Cargando…

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study

BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Jaehyun, Lee, Min Jung, Choe, Eun Yeong, Jung, Chang Hee, Wang, Hye Jin, Kim, Myoung Soo, Kim, Yu Seun, Park, Joong-Yeol, Kang, Eun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803553/
https://www.ncbi.nlm.nih.gov/pubmed/26754588
http://dx.doi.org/10.3803/EnM.2016.31.1.161
_version_ 1782422884158799872
author Bae, Jaehyun
Lee, Min Jung
Choe, Eun Yeong
Jung, Chang Hee
Wang, Hye Jin
Kim, Myoung Soo
Kim, Yu Seun
Park, Joong-Yeol
Kang, Eun Seok
author_facet Bae, Jaehyun
Lee, Min Jung
Choe, Eun Yeong
Jung, Chang Hee
Wang, Hye Jin
Kim, Myoung Soo
Kim, Yu Seun
Park, Joong-Yeol
Kang, Eun Seok
author_sort Bae, Jaehyun
collection PubMed
description BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes. METHODS: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor. RESULTS: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin. CONCLUSION: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes.
format Online
Article
Text
id pubmed-4803553
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-48035532016-03-27 Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study Bae, Jaehyun Lee, Min Jung Choe, Eun Yeong Jung, Chang Hee Wang, Hye Jin Kim, Myoung Soo Kim, Yu Seun Park, Joong-Yeol Kang, Eun Seok Endocrinol Metab (Seoul) Original Article BACKGROUND: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood levels of cyclosporine in renal transplant recipients with diabetes. METHODS: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or linagliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared according to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cyclosporine were also assessed 2 months after treatment with each DPP-4 inhibitor. RESULTS: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin –0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were significantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin. CONCLUSION: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. Korean Endocrine Society 2016-03 2016-03-16 /pmc/articles/PMC4803553/ /pubmed/26754588 http://dx.doi.org/10.3803/EnM.2016.31.1.161 Text en Copyright © 2016 Korean Endocrine Society http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bae, Jaehyun
Lee, Min Jung
Choe, Eun Yeong
Jung, Chang Hee
Wang, Hye Jin
Kim, Myoung Soo
Kim, Yu Seun
Park, Joong-Yeol
Kang, Eun Seok
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title_full Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title_fullStr Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title_full_unstemmed Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title_short Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
title_sort effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803553/
https://www.ncbi.nlm.nih.gov/pubmed/26754588
http://dx.doi.org/10.3803/EnM.2016.31.1.161
work_keys_str_mv AT baejaehyun effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT leeminjung effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT choeeunyeong effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT jungchanghee effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT wanghyejin effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT kimmyoungsoo effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT kimyuseun effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT parkjoongyeol effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy
AT kangeunseok effectsofdipeptidylpeptidase4inhibitorsonhyperglycemiaandbloodcyclosporinelevelsinrenaltransplantpatientswithdiabetesapilotstudy